Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
VERAXA Biotech Logo
VERAXA Biotech Growth Score
78
CB Rank
1127
Heat Score
95
VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation.
Founded
obfuscation
PublicPost-IPO Debt Heidelberg, Baden-Wurttemberg, Germany11-50 www.veraxa.com
Biotechnology
Financial Exchanges
Financial Services
Health Care
Medical
Overview

VERAXA Biotech
Total Funding
obfuscation
Growth Score
78
Heat Score
95

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score78
-14 pts
in past quarter
Heat Score 95
45 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About VERAXA Biotech

CB Rank
1127
VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation.
Founded
obfuscation
PublicPost-IPO Debt Heidelberg, Baden-Wurttemberg, Germany11-50 www.veraxa.com
Biotechnology
Financial Exchanges
Financial Services
Health Care
Medical

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Series B
OBF
in
obfuscation

Key People

  • Photo of Martin Haase
    Martin Haase: Chief Financial Officer & Executive, Strategy
  • Photo of Christoph Antz
    Christoph Antz: Co-Founder and Chief Executive Officer
    Past Role: VERAXA Biotech, Co-Founder & Chief Executive Officer

Details

Legal Name VERAXA Biotech GmbH
Also Known As Voyager Acquisition Corp., Velabs Therapeutics
Operating Status Active
Stock Symbol  NASDAQ:VRXA
Company Type For Profit
Founders  Christine Köhler, Christoph Antz, Christoph Merten, Edward Lemke
About the Company
VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation.
Phone Number +49 6221 387 8194
Contact Email info@voyageracq.com
Predictions & Insights

Growth Insight

See this Growth Insight
VERAXA Biotech is
Lorem
 to be growing
Top Contributing Factors
Merger or Acquisition

Growth Prediction

See this Growth Prediction

Products & Services

BiTAC Platform
A proprietary antibody discovery and engineering platform for generating bispecific antibody therapeutics.
Antibody Drug Conjugate (ADC) Technology
Technology for site-specific conjugation of cytotoxic drugs to antibodies using click chemistry for targeted cancer therapy.

Research & Development

VERAXA Biotech is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - VERAXA Biotech Logo
Post-IPO Debt - VERAXA Biotech
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - VERAXA Biotech Logo
Post-IPO Debt - VERAXA Biotech
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - VERAXA Biotech Logo
Post-IPO Debt - VERAXA Biotech
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - VERAXA Biotech Logo
Post-IPO Debt - VERAXA Biotech
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - VERAXA Biotech Logo
Post-IPO Debt - VERAXA Biotech
—
obfuscation
— Post-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - VERAXA Biotech Logo
Post-IPO Debt - VERAXA Biotech
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - VERAXA Biotech Logo
Post-IPO Debt - VERAXA Biotech
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - VERAXA Biotech Logo
Post-IPO Debt - VERAXA Biotech
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - VERAXA Biotech Logo
Post-IPO Debt - VERAXA Biotech
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - VERAXA Biotech Logo
Post-IPO Debt - VERAXA Biotech
—
obfuscation
— Post-IPO Debt

Investors

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 8 Board Members and Advisors 2 Contacts 4

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 28, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 27, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

284
-75.54%
 in past month

IT Spend

$274.9KThis year, VERAXA Biotech is projected to spend $274.9K on IT, according to Aberdeen.

Active Website Tech Count

5VERAXA Biotech is actively using 5 technologies for its website, according to BuiltWith. These include Common Crawl, CommonCrawl Top 50m, and  jsDelivr.

Total IP

9The intellectual property of VERAXA Biotech includes 4 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery. Additionally, VERAXA Biotech has registered 5 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is VERAXA Biotech's headquarters? VERAXA Biotech is located in Heidelberg, Baden-Wurttemberg, Germany.Who invested in VERAXA Biotech? VERAXA Biotech is funded by Lincoln Park Capital Fund.When was the last funding round for VERAXA Biotech? VERAXA Biotech closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are VERAXA Biotech's competitors? Alternatives and possible competitors to VERAXA Biotech may include Tubulis, CatalYm, and  Genmab.How much funding has VERAXA Biotech raised to date? VERAXA Biotech has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(2e7868f 1)
|